Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Nov 30;3(111):111cm33.
doi: 10.1126/scitranslmed.3002609.

Testing the right target and right drug at the right stage

Reisa A Sperling  1 , Clifford R Jack Jr, Paul S Aisen
Affiliations
Review

Testing the right target and right drug at the right stage

Reisa A Sperling et al. Sci Transl Med. .

Abstract

Alzheimer's disease (AD) is the only leading cause of death for which no disease-modifying therapy is currently available. Recent disappointing trial results at the dementia stage of AD have raised multiple questions about our current approaches to the development of disease-modifying agents. Converging evidence suggests that the pathophysiological process of AD begins many years before the onset of dementia. So why do we keep testing drugs aimed at the initial stages of the disease process in patients at the end-stage of the illness?

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Optimal stage for intervention? Shown is a scheme of the proposed stages of AD with potential prevention and treatment targets. We have depicted the hypothetical dynamic trajectories of currently available biomarkers of the AD pathophysiological process over the clinical course of the disease by plotting biomarker measurements (from normal to abnormal ranges) on the y-axis versus the defined clinical stages of AD on the x-axis. Primary prevention trials would occur in individuals who do not yet have evidence of AD pathology, whereas secondary prevention trials would occur in individuals who have evidence of early pathology on biomarkers of AD but do not yet have clinically evident symptoms, meeting criteria for MCI.
See this image and copyright information in PMC

References

    1. Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med. 2011;17:1060–1065. - PubMed
    1. Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, Pratico D, Saint Louis LA, Wallin A, Blennow K, de Leon MJ. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging. 2009;30:682–690. - PMC - PubMed
    1. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Langstrom B, Nordberg A. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456–1465. - PubMed
    1. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228–234. - PubMed
    1. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385–393. - PubMed